CINECA IRIS Institutional Research Information System

GRAGNANI, LAURA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 3.907
NA - Nord America 2.613
EU - Europa 2.145
SA - Sud America 445
AF - Africa 110
Continente sconosciuto - Info sul continente non disponibili 2
OC - Oceania 2
Totale 9.224
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.510
IT - Italia 1.362
SG - Singapore 1.244
CN - Cina 1.142
HK - Hong Kong 579
BR - Brasile 361
KR - Corea 288
VN - Vietnam 179
IN - India 137
DE - Germania 115
JP - Giappone 110
GB - Regno Unito 104
SE - Svezia 102
FR - Francia 94
CH - Svizzera 78
FI - Finlandia 74
RU - Federazione Russa 64
CA - Canada 39
BD - Bangladesh 37
ZA - Sudafrica 34
IQ - Iraq 32
MX - Messico 31
AR - Argentina 28
PL - Polonia 28
TR - Turchia 27
CI - Costa d'Avorio 26
AT - Austria 24
NL - Olanda 20
SA - Arabia Saudita 20
BG - Bulgaria 15
UA - Ucraina 15
PK - Pakistan 14
VE - Venezuela 13
CZ - Repubblica Ceca 12
UZ - Uzbekistan 12
JO - Giordania 11
ES - Italia 10
KE - Kenya 10
CL - Cile 9
CO - Colombia 9
MA - Marocco 8
PH - Filippine 8
EC - Ecuador 7
IE - Irlanda 7
NP - Nepal 7
TW - Taiwan 7
BB - Barbados 6
EG - Egitto 6
GT - Guatemala 6
ID - Indonesia 5
JM - Giamaica 5
PS - Palestinian Territory 5
PY - Paraguay 5
TN - Tunisia 5
UY - Uruguay 5
AE - Emirati Arabi Uniti 4
IL - Israele 4
SN - Senegal 4
TH - Thailandia 4
TT - Trinidad e Tobago 4
AO - Angola 3
BY - Bielorussia 3
DO - Repubblica Dominicana 3
DZ - Algeria 3
ET - Etiopia 3
GR - Grecia 3
IR - Iran 3
MY - Malesia 3
OM - Oman 3
PE - Perù 3
SY - Repubblica araba siriana 3
AM - Armenia 2
AU - Australia 2
BH - Bahrain 2
BO - Bolivia 2
CG - Congo 2
DK - Danimarca 2
GE - Georgia 2
HN - Honduras 2
HR - Croazia 2
KG - Kirghizistan 2
KZ - Kazakistan 2
LB - Libano 2
LT - Lituania 2
LY - Libia 2
NG - Nigeria 2
PA - Panama 2
SR - Suriname 2
TJ - Tagikistan 2
AL - Albania 1
AW - Aruba 1
AZ - Azerbaigian 1
BF - Burkina Faso 1
BN - Brunei Darussalam 1
BS - Bahamas 1
CR - Costa Rica 1
EE - Estonia 1
EU - Europa 1
GH - Ghana 1
GY - Guiana 1
Totale 9.211
Salva come PNG Salva come JPEG
Città #
Milan 795
Singapore 733
Hong Kong 569
Hefei 476
Santa Clara 430
Ashburn 370
San Jose 365
Seoul 286
Shanghai 245
Boardman 161
Dallas 160
Pisa 125
New York 124
Tokyo 106
Los Angeles 94
Rome 91
Beijing 81
Bern 72
Hyderabad 63
Council Bluffs 59
Fairfield 58
Helsinki 56
Ho Chi Minh City 55
Lauterbourg 55
London 50
Florence 45
Hanoi 43
Seattle 42
Frankfurt am Main 40
Munich 35
Redondo Beach 31
Woodbridge 31
Buffalo 30
São Paulo 29
Chicago 28
Abidjan 26
Warsaw 26
Houston 21
Wilmington 19
Nuremberg 18
Serra 16
Cambridge 15
Chandler 15
Ann Arbor 14
Johannesburg 14
Rio de Janeiro 13
Sofia 13
Tashkent 12
Amman 11
Istanbul 11
Turku 11
Baltimore 10
Chennai 10
Da Nang 10
Elk Grove Village 10
Fuzhou 10
Belo Horizonte 9
Cape Town 9
Dhaka 9
Falkenstein 9
Mexico City 9
Baghdad 8
Brno 8
Lucknow 8
Nairobi 8
Pune 8
San Francisco 8
Vienna 8
Dublin 7
Montreal 7
Mumbai 7
Orem 7
Ottawa 7
Riyadh 7
Bridgetown 6
Erbil 6
Guatemala City 6
Hải Dương 6
Lawrence 6
Porto Alegre 6
Salt Lake City 6
San Giuliano Terme 6
Zhengzhou 6
Brookline 5
Brooklyn 5
Cairo 5
Dammam 5
Durban 5
Haiphong 5
Jeddah 5
Medford 5
New Delhi 5
Phoenix 5
Princeton 5
Shenzhen 5
Zurich 5
Amsterdam 4
Barquisimeto 4
Bologna 4
Buenos Aires 4
Totale 6.616
Salva come PNG Salva come JPEG
Nome #
B-cell activating factor (BAFF), BAFF promoter and BAFF receptor allelic variants in hepatitis C virus related Cryoglobulinemic Vasculitis and Non-Hodgkin's Lymphoma 202
Thyroid Autoimmunity and SARS-CoV-2 Infection 153
Mixed cryoglobulinemia syndrome is a negative prognostic factor in the standard of care (Peg-IFN+ribavirin) anti-HCV therapy 151
IgG cryoglobulinemia 149
International therapeutic guidelines for patients with HCV-related extrahepatic disorders. A multidisciplinary expert statement 143
Genome-wide association study of hepatitis C virus- and cryoglobulin-related vasculitis 141
COVID-19 and Mixed Cryoglobulinemia Syndrome: Long-Term Survey Study on the Prevalence and Outcome, Vaccine Safety, and Immunogenicity 140
Flares of mixed cryoglobulinaemia vasculitis after vaccination against SARS-CoV-2 138
A prospective study of direct-acting antiviral effectiveness and relapse risk in HCV cryoglobulinemic vasculitis by the Italian PITER cohort 138
Hepatitis C virus-related mixed cryoglobulinemia: is genetics to blame? 137
Interferon-free therapy in hepatitis C virus mixed cryoglobulinaemia: a prospective, controlled, clinical and quality of life analysis 134
A serum metabolomic analysis of HCV-infected patients successfully treated with IFN-free DAA regimens 130
Role of MicroRNA Profile Modifications in Hepatitis C Virus-Related Mixed Cryoglobulinemia 127
HCV-related rheumatic manifestations and therapeutic strategies 127
P0752 : NOTCH4 and MHC class II polymorphisms contibute to HCV-related benign and malignant lymphoproliferative diseases 126
Impaired immunogenicity to COVID-19 vaccines in autoimmune systemic diseases. High prevalence of non-response in different patients’ subgroups 126
Sofosbuvir/Velpatasvir for the treatment of Hepatitis C Virus infection 125
Autoimmunity and lymphoproliferation markers in naïve HCV-RNA positive patients without clinical evidences of autoimmune/lymphoproliferative disorders 125
Different biochemical patterns in type II and type III mixed cryoglobulinemia in HCV positive patients 124
Virus-driven autoimmunity and lymphoproliferation: the example of HCV infection 123
Assessment of free light chains in HCV-positive patients with mixed cryoglobulinaemia vasculitis undergoing rituximab treatment 122
Could the presence of Mixed Cryoglobulinemia influence the outcome of standard peg-IFN plus ribavirin anti-HCV therapy? 122
MicroRNA expression in hepatitis C virus-related malignancies: A brief review 122
Host genetic determinants in HCV-related mixed cryoglobulinemia 121
Long-term outcome of HCV-related mixed cryoglobulinemia in patients achieving sustained viral sustained viral response (SVR) after antiviral therapy 121
Long-term effect of HCV eradication in patients with mixed cryoglobulinemia: A prospective, controlled, open-label, cohort study 121
Hepatitis C-associated B-cell non-Hodgkin lymphomas: The emerging role of miRNA-26 120
HCV-related mixed cryoglobulinemia: Data from PITER, a nationwide Italian HCV cohort study 119
HCV and lymphoproliferation 119
HERG K+ channels activation during beta(1) integrin-mediated adhesion to fibronectin induces an up-regulation of alpha(v)beta(3) integrin in the preosteoclastic leukemia cell line FLG 29.1 118
Combined treatment with antiviral therapy and rituximab in patients with mixed cryoglobulinemia: review of the literature and report of a case using direct antiviral agents-based antihepatitis C virus therapy 118
Covid-19 And Rheumatic Autoimmune Systemic Diseases: Role of Pre-Existing Lung Involvement and Ongoing Treatments 118
Value of IL28B genotyping in patients with HCV-related mixed cryoglobulinemia: results of a large, prospective study 117
Detection of WA B Cells in HCV Infection by Molecular Analysis: A Prognostic Marker for Cryoglobulinemic Vasculits and B Cell Lymphomas 115
Detection of bcl-2 rearrangement in mucosa-associated lymphoid tissue lymphomas from patients with hepatitis C virus infection 115
Treatment of HCV-related mixed cryoglobulinemia 115
The Hepatitis C Virus Infection as a Systemic Disease 114
Impact of COVID-19 and vaccination campaign on 1,755 systemic sclerosis patients during first three years of pandemic. Possible risks for individuals with impaired immunoreactivity to vaccine, ongoing immunomodulating treatments, and disease-related lung involvement during the next pandemic phase 114
Assessment of liver stiffness in patients with HCV and mixed cryoglobulinemia undergoing rituximab treatment 113
microRNA PROFILE MODIFICATIONS IN HEPATITIS C VIRUS-RELATED MIXED CRYOGLOBULINEMIA 113
MIR-17/92 EXPRESSION PATTERN: A MOLECULAR SIGNATURE OF HCV-RELATED MIXED CRYOGLOBULINEMIA 113
Bcl-2 rearranged B cell clones in chronic HCV infection: a possible factor negatively influencing the virological response to treatment 113
Plasma PAF-AH biological activity decreases in patients with HCV chronic infection 109
HBV and HCV testing outcomes among marginalized communities in Italy, 2019–2024: a prospective study 109
NOTCH4 AND MHC CLASS II POLYMORPHISMS CONTRIBUTE TO HCV-RELATED BENIGN AND MALIGNANT LYMPHOPROLIFERATIVE DISEASES 109
Can BAFF promoter polymorphism be a predisposing condition for HCV-related mixed cryoglobulinemia? 108
HCV infection, malignancy and liver transplantation 108
Genetic determinants in Hepatitis C Virus-associated mixed cryoglobulinemia: role of polymorphic variants of BAFF promoter and Fc-gamma receptors 107
Non-Invasive B-Cell Clonality Markers May Help in the Rational Approach to HCV Svr Cryoglobulinemic Patients with Persisting Manifestations 107
Prevalence and Death Rate of COVID-19 in Autoimmune Systemic Diseases in the First Three Pandemic Waves. Relationship with Disease Subgroups and Ongoing Therapies 104
HCV-related lymphatic and hepatic malignancies are associated with different microRNA expression patterns in PBMCs 104
Thyroid autoimmunity and SARS-CoV-2 infection: Report of a large Italian series 103
Role of notch receptors in hematologic malignancies 97
HCV AND lymphoma: Genetic and epigenetic factors 92
Regression of t(14;18) bearing B-cell clones following antiviral therapy in chronic HCV infection 88
Opposite Effects of mRNA-Based and Adenovirus-Vectored SARS-CoV-2 Vaccines on Regulatory T Cells: A Pilot Study 88
Absent or suboptimal response to booster dose of COVID-19 vaccine in patients with autoimmune systemic diseases 85
Hematological and Genetic Markers in the Rational Approach to Patients With HCV Sustained Virological Response With or Without Persisting Cryoglobulinemic Vasculitis 81
Assessment of Free Light Chains in HCV positive patients undergoing Rituximab treatment 79
IL28B POLYMORPHISM AS PREDICTOR OF RESPONSE TO ANTI-HCV THERAPY IN HCV-RELATED MIXED CRYOGLOBULINEMIA SYNDROME 78
null 74
MIR-17/92 EXPRESSION PATTERN: A MOLECULAR SIGNATURE OF HCV-RELATED MIXED CRYOGLOBULINEMIA 69
Host genetic determinants in HCV-related mixed cryoglobulinemia 68
Hepatitis B virus-infection related cryoglobulinemic vasculitis. Clinical manifestations and the effect of antiviral therapy: A review of the literature 65
High prevalence of past hepatitis B virus infection in diffuse large B cell lymphoma: a retrospective study from Italy 65
DNA Damage Response Protein CHK2 Regulates Metabolism in Liver Cancer 61
Response to IFN-based antiviral therapy and long term effect of HCV eradication in Mixed Cryoglobulinemia, with or without symptoms: a prospective, controlled, open-label, long term, cohort study 61
COVID-19 AND CRYOGLOBULINEMIC VASCULITIS. LONG-TERM SURVEY STUDY ON THE IMPACT OF PANDEMIC AND VACCINATION ON A LARGE PATIENT'S POPULATION 60
Evaluation of Plasma miR-17-5p, miR-24-3p and miRNA-223-3p Profile of Hepatitis C Virus-Infected Patients after Treatment with Direct-Acting Antivirals 59
Dual stimulation by autoantigen and CpG fosters the proliferation of exhausted rheumatoid factor-specific CD21low B cells in hepatitis C virus-cured mixed cryoglobulinemia 58
COVID-19 vaccine immunogenicity in 16 patients with autoimmune systemic diseases. Lack of both humoral and cellular response to booster dose and ongoing disease modifying therapies 58
Hepatitis C virus lymphotrophism: lessons from a decade of studies 58
Free light chains: Eclectic multipurpose biomarker 53
Hepatitis C virus-associated B-cell lymphomas: The importance of the new direct antiviral agent therapy 52
Rapid improvement of psychiatric stigmata after IFN-free treatment in HCV patients with and without cryoglobulinemic vasculitis 51
Triple antiviral therapy in hepatitis C virus infection with or without mixed cryoglobulinaemia: A prospective, controlled pilot study 51
Modifications of plasma platelet-activating factor (PAF)- acetylhydrolase/PAF system activity in patients with chronic hepatitis C virus infection 50
Virological and clinical response to interferon-free regimens in patients with HCV-related mixed cryoglobulinemia: Preliminary results of a prospective pilot study 49
Hepatitis b virus-related cryoglobulinemic vasculitis: Review of the literature and long-term follow-up analysis of 18 patients treated with nucleos(t)ide analogues from the italian study group of cryoglobulinemia (gisc) 48
Prospective study of guideline-tailored therapy with direct-acting antivirals for hepatitis C virus-associated mixed cryoglobulinemia 45
Fibrosis assessment in patients with HCV or HBV chronic infection 43
Predictors of long-term cryoglobulinemic vasculitis outcomes after HCV eradication with direct-acting antivirals in the real-life 42
A stereotyped light chain may shape virus-specific B-cell receptors in HCV-dependent lymphoproliferative disorders 42
Solving the mystery of HBV-related mixed cryoglobulinemia: potential biomarkers of disease progression 41
Response to IFN-based antiviral therapy and long term effect of HCV eradication in Mixed Cryoglobulinemia, with or without symptoms: a prospective, controlled, open-label, long term, cohort study 41
Exploratory study of extracellular matrix biomarkers for non-invasive liver fibrosis staging: A machine learning approach with XGBoost and explainable AI 39
Deregulation of microRNA expression in peripheral blood mononuclear cells from patients with HCV-related malignancies 39
KDM2A chromatin regulator constrains senescence program and immunoresponse in liver cancer 39
HIGH SVR RATES WITH SMV plus SOF IN HCV GT1 AND GT4 PATIENTS WITH CIRRHOSIS OR ADVANCED FIBROSIS: A REAL PRACTICE ANALYSIS FROM A LARGE REGIONAL DATABASE IN TUSCANY, ITALY 37
Longitudinal evaluation of liver stiffness and outcomes in patients with chronic hepatitis C before and after short- and long-term IFN-free antiviral treatment 37
Regression of T(14;18) bearing B-cell clones following antiviral therapy in chronic HCV infection 37
Deregulation of microRNA expression in peripheral blood mononuclear cells from patients with HCV-related malignancies 36
Sentinel biomarkers in HCV positive patients with mixed cryoglobulinemia 35
The Relevance of MicroRNAs in the Pathogenesis and Prognosis of HCV-Disease: The Emergent Role of miR-17-92 in Cryoglobulinemic Vasculitis 31
Early decrease of T-bet+ B cells during subcutaneous belimumab predicts response to therapy in systemic lupus erythematosus patients 31
Effect of chronic hepatitis C virus infection on inflammatory lipid mediators 31
Presence of BCL-2 rearranged B-cell clones in chronic HCV infection may negatively influence virological response to treatment 30
PDCD1 and IFNL4 genetic variants and risk of developing hepatitis C virus-related diseases 29
Il polimorfismo dell'interleuchina 28B come predittore di risposta in pazienti con crioglobulinemia mista HCV-correlata 29
Notch4 and mhc class II polymorphisms are associated with hcv-related benign and malignant lymphoproliferative diseases 29
Totale 8.971
Salva come PNG Salva come JPEG
Categoria #
all - tutte 30.323
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 30.323
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20215 0 0 0 0 0 0 0 0 0 0 0 5
2021/202275 0 1 5 4 8 15 1 6 2 12 5 16
2022/2023449 8 6 10 4 4 11 257 19 87 11 23 9
2023/20241.613 277 230 325 178 248 134 20 26 5 22 12 136
2024/20253.658 126 134 40 122 323 238 249 120 304 322 548 1.132
2025/20263.502 248 608 304 306 410 231 557 157 249 246 95 91
Totale 9.534